FDA approval for Gilead's HCV drug

Discussion in 'Gilead Sciences' started by Ashton Alloway, Jul 18, 2017 at 4:32 PM.

  1. Ashton Alloway

    Ashton Alloway new user

    Joined:
    Jul 7, 2017
    Messages:
    7
    Likes Received:
    0

  2. anonymous

    anonymous Guest

    Unfortunately, the drug is inferior to Abbvie's.
     
  3. anonymous

    anonymous Guest

    AbbVie's combination of glecaprevir and pibrentasvir looks likely to gain approval as an eight-week regimen in all genotypes of hepatitis C and in patients who've never undergone treatment. Gilead's Harvoni is approved as an eight-week regimen, but only in one subset of patients. AbbVie will price its two-pill drug like its Viekira Pak, another hepatitis C combination that goes for about $28,000 per month. AbbVie will aggressively market the two-drug combo against Gilead's Harvoni and Epclusa, he said.
    This strategy is likely to result in significant market share for AbbVie, given the convenience and excellent efficacy of their two-drug combination
     
  4. anonymous

    anonymous Guest

    Turn out the lights, the party's over. Not good folks, not good. Is Abv hiring?
     
  5. anonymous

    anonymous Guest

    I hope the Karma bitch bites everyone here hard, especially KD in the northeast....total douche. Everyone else with a hair across their ass that we were the only game in town deserves whatever comes along. Pompous shit heads
     
  6. anonymous

    anonymous Guest

     
  7. anonymous

    anonymous Guest

    agree....KD.......